New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
08:11 EDTGHDXGenomic Health's Oncotype DX colon cancer survey shows positive impact
Genomic Health announced results from the Oncotype DX colon cancer test studies highlighting the body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions. Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test increased concordance between physician and patient treatment choice from 66% to 96%, that the quantitative information provided by the Recurrence Score result influenced a majority of patients' treatment decisions and physicians' treatment recommendations, and increased physicians' confidence in their own recommendations. Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:05 EDTGHDXGenomic Health announces positive results for validation study of Oncotype DX
Genomic Health announced strongly positive results from an additional independent clinical validation study of the Oncotype DX prostate cancer test. This new large study reconfirmed the biopsy-based test's Genomic Prostate Score as a predictor of adverse pathology at surgery and, for the first time, validated GPS as a strong independent predictor of a rise in prostate-specific antigen following surgery. In meeting these two endpoints, the Oncotype DX prostate cancer test provides both clinically actionable and long-term outcomes information for men with newly diagnosed low- and intermediate-risk prostate cancer. Furthermore, the study demonstrated that Oncotype DX is similarly predictive of outcomes in both Caucasian and African-American men. The Oncotype DX GPS was also significantly predictive of metastatic prostate cancer recurrence, a notable finding given the likelihood of metastases in patients with low- and intermediate-risk prostate cancer is so small.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use